These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34020007)

  • 1. Hi3 + 3: A model-assisted dose-finding design borrowing historical data.
    Duan Y; Wang SJ; Ji Y
    Contemp Clin Trials; 2021 Oct; 109():106437. PubMed ID: 34020007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
    Zhao Y; Liu R; Takeda K
    Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elastic priors to dynamically borrow information from historical data in clinical trials.
    Jiang L; Nie L; Yuan Y
    Biometrics; 2023 Mar; 79(1):49-60. PubMed ID: 34437714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating historical information to improve phase I clinical trials.
    Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
    Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian hierarchical model for dose-finding trial incorporating historical data.
    Han L; Deng Q; He Z; Fleischer F; Yu F
    J Biopharm Stat; 2024 Aug; 34(5):646-660. PubMed ID: 37676029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
    Harun N; Liu C; Kim MO
    Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A scaled kernel density estimation prior for dynamic borrowing of historical information with application to clinical trial design.
    Warren JL; Wang Q; Ciarleglio MM
    Stat Med; 2024 Apr; 43(8):1615-1626. PubMed ID: 38345148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
    Takeda K; Morita S
    Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
    Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
    Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
    Zhang W; Pan Z; Yuan Y
    J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
    Feißt M; Krisam J; Kieser M
    Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity.
    Xu Z; Lin X
    Stat Methods Med Res; 2022 Mar; 31(3):534-548. PubMed ID: 34806915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2023 May; 14(3):396-413. PubMed ID: 36625478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unit information prior for adaptive information borrowing from multiple historical datasets.
    Jin H; Yin G
    Stat Med; 2021 Nov; 40(25):5657-5672. PubMed ID: 34302378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.
    Su L; Chen X; Zhang J; Yan F
    JCO Precis Oncol; 2022 Mar; 6():e2100394. PubMed ID: 35263169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
    Wang X; Suttner L; Jemielita T; Li X
    J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.